
Venture capital
NeXeption Capital
NeXeption Capital is a life sciences investor-operator that forms and runs drug development companies around clinical assets, and has a fund structure launched in 2025 to finance them.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is NeXeption Capital right for your round?
Key stats
Fund cycle Public record
No fund vehicles on the public registers we read.
Latest investments
Rounds NeXeption Capital joined, from press and the firm’s own posts.
Every round NeXeption Capital joined
Round sizes, NeXeption Capital’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company NeXeption Capital backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet NeXeption Capital
Events where NeXeption Capital’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
NeXeption Capital is based in the United States.
The firm builds biotech companies around de-risked clinical assets, pairs them with experienced operating teams, and argues that life sciences offers large impact and high-margin returns once a drug is approved. From the firm’s own website.
NeXeption Capital lists 12 portfolio companies on its website, including ItchBio, NexEos Bio, Uniquity Bio, Aclaris Therapeutics and Akarna Therapeutics.
Firms whose websites list some of the same companies include Aperture Venture Partners, LUMIRA VENTURES and New Science Ventures.
Know before NeXeption Capital’s next round is announced.
PRO tracks NeXeption Capital’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.